ArticleNature communications2020
Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Hepatitis E Virus Infection in Pregnant Women.Microorganisms · 2026Review
- No more than three PlpE non-overlapping epitopes trigger significant antibody production in individuals vaccinated with theMicrobiology spectrum · 2026Article
- The crucial but insufficient role of E2s domain's residues 490 and 492 in determining the host tropism of hepatitis E virus.Nature communications · 2026Article
- Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025Article
- Immunogenicity and memory B-cell potency induced by an inactivated COVID-19 vaccine in pregnant women.Molecular medicine (Cambridge, Mass.) · 2025Article
- Design and Analysis of Novel HEV Vaccine Variants and Evaluation of Two Selected Candidates in a Porcine Infection Model.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Article
- Structural basis for hepatitis E virus neutralization by potent human antibodies.Science advances · 2025Article
- Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody.Scientific reports · 2025Article
- Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice.Nature communications · 2025Article
- Current knowledge on the epidemiology and detection methods of hepatitis E virus in China.Virology journal · 2024Review
- Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus.Nature communications · 2024Article
- Lipid A-modified Escherichia coli can produce porcine parvovirus virus-like particles with high immunogenicity and minimal endotoxin activity.Microbial cell factories · 2024Article
- A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers.bioRxiv : the preprint server for biology · 2024Article
- ELISA-R: an R-based method for robust ELISA data analysis.Frontiers in immunology · 2024Article
- Redeveloping antigen detection kits for the diagnosis of rat hepatitis E virus.Journal of clinical microbiology · 2023Article
- Review
- Article
- Combinations but Not a Single PlpE Epitope Induces Host Protective Immunity against Pasteurella multocida.Infection and immunity · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 2 countries.
Funding
Abstract
Efficacy evaluation through human trials is crucial for advancing a vaccine candidate to clinics. Next-generation sequencing (NGS) can be used to quantify B cell repertoire response and trace antibody lineages during vaccination. Here, we demonstrate this application with a case study of Hecolin®, the licensed vaccine for hepatitis E virus (HEV). Four subjects are administered the vaccine following a standard three-dose schedule. Vaccine-induced antibodies exhibit a high degree of clonal diversity, recognize five conformational antigenic sites of the genotype 1 HEV p239 antigen, and cross-react with other genotypes. Unbiased repertoire sequencing is performed for seven time points over six months of vaccination, with maturation pathways characterize for a set of vaccine-induced antibodies. In addition to dynamic repertoire profiles, NGS analysis reveals differential patterns of HEV-specific antibody lineages and highlights the necessity of the long vaccine boost. Together, our study presents a quantitative strategy for vaccine evaluation in small-scale human studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.